What drugs does THROMBOGENICS, INC make?

THROMBOGENICS, INC has 1 FDA-approved drugs including JETREA.

What therapeutic areas does THROMBOGENICS, INC focus on?

THROMBOGENICS, INC focuses primarily on Ophthalmology and Metabolic.

← Back

Data updated: Mar 10, 2026

THROMBOGENICS, INC

OphthalmologyMetabolic

Biotech

THROMBOGENICS, INC is a biotechnology company focused on Ophthalmology, Metabolic. Key products include JETREA.

2012

Since

Drugs

Trials

Approved (2yr)

Key Drugs

JETREA

ocriplasmin

· 2012

Recent Activity

No recent activity

SEC Filings ProEarly access

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Ophthalmology 75%

0 drugs Phase 2: 2 Phase 1: 2

Metabolic 25%

0 drugs Phase 1: 2

Pipeline Strength ProEarly access

Competitors ProEarly access

OTSUKA ICU MEDCL specialty

Metabolic, Ophthalmology

Bayer big-pharma

Ophthalmology, Metabolic

B BRAUN specialty

Ophthalmology, Metabolic

ASTELLAS specialty

Metabolic, Ophthalmology

UPJOHN big-pharma

Metabolic, Ophthalmology

THROMBOGENICS, INC

Key Drugs

Recent Activity

Therapeutic Focus

Pipeline Strength ProEarly access

Competitors ProEarly access

All Drugs (1)

Active (1)

Discontinued (0)

Company Info